Vima Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
Overview
A preclinical company developing neuroprotective small molecules for ALS and other neurodegenerative diseases.
NeuroscienceNeurodegenerative Diseases
Technology Platform
A small molecule platform targeting the integrated stress response (ISR) pathway to achieve neuroprotection in degenerative brain diseases.
Funding History
1Total raised:$60M
Series A$60M
Opportunities
Potential to develop a first-in-class disease-modifying therapy for ALS, a condition with severe unmet need and limited treatment options.
Risk Factors
Extremely high translational risk, as many neuroprotective strategies have failed to show efficacy when moving from animal models to human patients.
Competitive Landscape
Enters a competitive ALS landscape with a novel mechanism, facing companies like Amylyx Pharmaceuticals and Biogen.